Amerinet Inc. News
Derma Sciences Signs With Amerinet for MEDIHONEY(TM) Wound & Burn Dressings
"This agreement continues the momentum that MEDIHONEY has been building since we have made it a key part of our product portfolio," said
The MEDIHONEY line of dressings, containing Active Leptospermum Honey, is used for managing a wide variety of wounds and burns. In July, the FDA gave its initial clearance of MEDIHONEY, and the product was launched last fall. Two additional clearances for line extensions have been granted since that time. Sales have increased rapidly, and over 20 clinical abstracts on the use of the product have been accepted at various professional conferences so far in 2008.
"Amerinet continuously looks for new and emerging technology products that are both unique in the marketplace and that will be of benefit to our member facilities," said
About Amerinet Inc.
Through Total Spend Management Solutions, Amerinet strategically partners with health care providers to improve operating margins by creating efficiencies, reducing costs and identifying new revenue streams. Supported by a team of clinical, data and supply chain experts, Amerinet offers a suite of tools, programs and services including a comprehensive and competitive portfolio that delivers practical solutions to address members' specific needs.
Based in
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand - the licensor of the patented honey- based technology - and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large scale randomized controlled trial on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.
Forward-looking Statements
Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.
Contact: Derma Sciences Inc Allen & Caron Inc Edward J. Quilty Rudy Barrio (US Investors) Chairman and CEO r.barrio@allencaron.com equilty@dermasciences.com (609) 514-4744 Brian Kennedy (media) brian@allencaron.com (212) 691-8087
SOURCE Derma Sciences, Inc.
Search Our News Using Google Search
Can't find what you want? Try using Google:
